On November 16, JD HEALTH recorded an Intraday Rise of 3.49% in Regular Trading, trading at HK$42.14, with turnover of HK$69.14 million.
The move coincided with the company disclosing during the import expo that it would centrally sign cooperation agreements with more than 20 global healthcare brands, spanning innovative drugs, nutrition and health products, and medical devices.
Background details indicate the partners include Pfizer, Merck, Novo, Omron, and Siemens. The company has already established deep cooperation with global top-50 multinational pharmaceutical companies, and online first launches exceeded 100 new drugs in the first three quarters, above the full-year total of last year. Earlier disclosed interim results showed revenue of RMB409 billion in the first half, up 15.9%, while adjusted net profit rose 40.3% to RMB35 billion, reflecting continued strengthening in its pharmaceutical retail and healthcare service platform capabilities.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments